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ABSTRACT
Objective We surveyed UK practice and compliance 
with the National Institute for Health and Care Excellence 
(NICE) ‘recent- onset chest pain’ guidance (Clinical 
Guideline 95, 2016) as a service quality initiative. We 
aimed to evaluate the diagnostic utility and efficacy of CT 
coronary angiography (CTCA), NICE- guided investigation 
compliance, invasive coronary angiography (ICA) use and 
revascularisation.
Methods A prospective analysis was conducted in 
nine UK centres between January 2018 and March 
2020. The reporter decided whether the CTCA was 
diagnostic. Coronary artery disease was recorded 
with the Coronary Artery Disease–Reporting and Data 
System (CAD- RADS). Local electronic records and 
picture archiving/communication systems were used 
to collect data regarding functional testing, ICA and 
revascularisation. Duplication of coronary angiography 
without revascularisation was taken as a surrogate for ICA 
overuse.
Results 5293 patients (mean age, 57±12 years; body 
mass index, 29±6 kg/m²; 50% men) underwent CTCA, with 
a 96% diagnostic scan rate. 618 (12%) underwent ICA, of 
which 48% (298/618) did not receive revascularisation. 
3886 (73%) had CAD- RADS 0–2, with 1% (35/3886) 
undergoing ICA, of which 94% (33/35) received ICA as a 
second- line test. 547 (10%) had CAD- RADS 3, with 23% 
(125/547) undergoing ICA, of which 88% (110/125) chose 
ICA as a second- line test, with 26% (33/125) leading to 
revascularisation. For 552 (10%) CAD- RADS 4 and 91 (2%) 
CAD- RADS 5 patients, ICA revascularisation rates were 
64% (221/345) and 74% (46/62), respectively.
Conclusions While CTCA for recent- onset chest pain 
assessment has been shown to be a robust test, which 
negates the need for further investigation in three- quarters 
of patients, subsequent ICA overuse remains with almost 
half of these procedures not leading to revascularisation.
INTRODUCTION
The 2016 iteration of the National Institute 
for Health and Care Excellence (NICE) 
guidance for the assessment and diagnosis of 
recent- onset chest pain of suspected cardiac 
origin (Clinical Guideline 95 (CG95)) recom-
mends diagnostic testing when stable angina 
cannot be excluded by clinical assessment 
alone.1 The first- line diagnostic test suggested 
is CT coronary angiography (CTCA). The 
guideline then recommends additional 
diagnostic investigation that may be needed 
following a CTCA, when evidence of coro-
nary artery disease (CAD) of uncertain func-
tional significance is found or the scan is 
non- diagnostic. In these circumstances, non- 
invasive functional imaging for myocardial 
ischaemia is recommended. The rationale 
for this is that there is little logic in following 
one anatomical test with another. Invasive 
Key questions
What is already known about this subject?
 ► The 2016 iteration of the National Institute for 
Health and Care Excellence (NICE) guidance for the 
assessment and diagnosis of recent- onset chest 
pain of suspected cardiac origin (Clinical Guideline 
95 (CG95 2016)) is clear in its recommendations re-
garding non- invasive cardiac imaging tests. What is 
not known is the diagnostic utility and efficacy of CT 
coronary angiography (CTCA) used in this context, 
the level of NICE compliance and whether invasive 
coronary angiography (ICA) is being overused.
What does this study add?
 ► In routine clinical use, CTCA, for recent- onset chest 
pain assessment, has been shown to be a robust 
test, undertaken with gender equality, which ne-
gates the need for further investigation in 73% of 
patients. However, ICA overuse is suggested by 48% 
of patients undergoing ICA but not revascularisa-
tion. Only 6% of patients with a moderate stenosis 
undergo revascularisation, but ICA was commonly 
used as second- line investigation in this subgroup, 
contrary to NICE CG95 (2016).
How might this impact on clinical practice?
 ► Service quality improvement may be achieved by 
taking the onward revascularisation rate into ac-
count when considering the need for onward testing 
and then following NICE CG95 (2016) second- line 
investigation recommendations and avoiding ‘stand- 
alone’ diagnostic ICA after CTCA wherever possible. 
These measures may reduce the number of patients 
undergoing ICA with no resulting revascularisation.
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coronary angiography (ICA) is therefore reserved as a 
third- line investigation.
Data from North America suggest that 66% of patients 
with moderate coronary stenosis on CTCA undergo ICA 
within 30 days and that <10% of these are both symp-
tomatic and receiving antianginal drug therapy.2 In the 
UK, single- centre data from 2016 showed that after a 
diagnostic CTCA, 42% of patients who underwent ICA 
did not have subsequent revascularisation.3 Diagnostic 
ICA following CTCA, without subsequent revasculari-
sation, may have a heterogeneous aetiology. Neverthe-
less, it commonly represents unnecessary duplication 
of anatomical testing and may be taken as a surrogate 
marker for overuse of ICA. This brings with it attendant 
concerns over timeliness, cost and safety.
Through collaboration with the British Society of 
Cardiovascular Imaging/British Society of Cardiovascular 
Computed Tomography (BSCI/BSCCT), we performed 
a service quality improvement initiative concerning 
patients across the UK referred for CTCA, following 
recent- onset chest pain assessment, according to NICE 
CG95 (2016). The aims were to evaluate the diagnostic 
utility and efficacy of CTCA in ‘real- world’ UK practice, 
to assess compliance with NICE- guided second- line inves-
tigation and to assess the use of ICA and revascularisa-
tion. This report of the initiative has been completed with 
reference to the revised standards for quality improve-
ment reporting excellence template (SQUIRE 2).4
METHODS
Study design
This is a multicentre, prospective analysis of the onward 
investigation and treatment of patients with suspected 
stable CAD assessed for recent- onset chest pain symptoms 
with CTCA. Centres across the UK undertaking CTCA 
in accordance with NICE CG95 (2016) were offered 
the opportunity to collect prospective data on patients 
attending for CTCA through email communication from 
the BSCI/BSCCT. It was a requirement that centres had 
access to information on subsequent activity for patients. 
The study was registered as a national audit and service 
evaluation in Plymouth (National audit of downstream 
testing after CTCA following NICE CG95 (2016) refer-
ence: CA_2017-18-191)). Centres agreeing to collect data 
registered with their local audit departments. Written 
informed consent and ethical approval were not obtained 
as patient care was not affected. Only fully anonymised 
data were transferred and used in the analysis.
Data collection
Each site was required to make two data collections: base-
line data and follow- up data, within 12 months. Baseline 
data were collected for consecutive patients, fulfilling 
NICE CG95 (2016) referral criteria at the time of the 
CTCA, by 10 centres across the UK between January 
2018 and March 2019. Local electronic patient records 
and picture archiving/communication systems were then 
used to collect follow- up data, which was completed by 
March 2020.
The first data collection covered demographic infor-
mation and CTCA results. Demographic information 
included age, sex and body mass index (BMI). The 
reporting cardiologist or radiologist decided whether 
the CTCA was diagnostic or not, primarily based on 
their own criteria. For all diagnostic CTCA, the Coro-
nary Artery Disease–Reporting and Data System (CAD- 
RADS) score was provided (CAD- RADS 0=0% coronary 
stenosis; CAD- RADS 1=1%–24%; CAD- RADS 2=25%–
49%; CAD- RADS 3=50%–69%; CAD- RADS 4=70%–
99%; CAD- RADS 5=100% or coronary occlusion), with 
the most severe stenosis defining the patient’s score.5 6 
The ability to provide a CAD- RADS score was recom-
mended to reporting centres as a secondary method 
of defining a diagnostic CTCA. The CAD- RADS score 
was then categorised into three groups (CAD- RADS 0, 
normal coronary arteries; CAD- RADS 1–2, atheroma 
probably not associated with ischaemia; CAD- RADS 
3–5, atheroma possibly or probably associated with 
ischaemia)
The second data collection pertained to the comple-
tion of the patient’s diagnostic pathway. Once a decision 
regarding onward investigation or treatment after CTCA 
had been made, and any functional testing for ischaemia, 
ICA or revascularisation by means of percutaneous inter-
vention (PCI) or coronary artery bypass surgery (CABG) 
had been carried out, the data collection was complete. If 
fractional flow reserve derived from CT (FFRCT; Heart-
flow, Redwood City, California, USA) was used or func-
tional testing for ischaemia was carried out to facilitate 
the decision- making process regarding the need for ICA, 
then this was recorded. If patients presented urgently or 
emergently while planned investigations were pending 
and underwent further investigation or treatment, then 
these data were included in the analysis. Data collection 
did not allow for re- presentation or reinvestigation of 
stable chest pain symptoms.
All data were then anonymised at the collecting site 
and collated in Plymouth at the registered national audit 
centre. One centre submitted uninterpretable data and 
was excluded from the analysis, resulting in nine centres 
contributing.
Statistical analysis
Data pertaining to the entire population are referred 
to as total population data, and when patients with non- 
diagnostic scans have been excluded, they are referred 
to as the diagnostic population. Patient age and BMI are 
given in the text as mean±SD, and ranges are given in 
tables. Ordinal categorical variables (CAD- RADS scores) 
are presented as number (percentage) and graphically 
displayed in bar charts. Percentage and proportional 
data are presented in tables. Descriptive statistical anal-
ysis was performed using SPSS software statistics V.23 
(SPSS).
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The total population contained data from 5293 patients. 
Patients had a mean age of 57±12 years, mean BMI 
of 29±6 kg/m², and 50% were men and 50% women 
(table 1). Overall, 96% of CTCA were diagnostic.
The CAD- RADS distribution is given in figure 1. For 
the 5076 diagnostic population, 1976 (39%) had normal 
coronary arteries (CAD- RADS 0), 1910 (38%) had 
atheroma probably not associated with ischaemia (CAD- 
RADS 1–2) and 1190 (23%) had atheroma possibly or 




Of the total population, 416 (8%) underwent functional 
testing after CTCA, and of these, 399 (96%) did not 
undergo subsequent revascularisation. Three centres 
submitted FFRCT data; however, the total numbers were 
modest at 208 (4% of diagnostic population). Of these, 
88% (183/208) did not undergo revascularisation, but 
no other subgroup analysis was made. Of the total popu-
lation, 618 (12%) patients underwent ICA, with 298 
(48%) of these receiving no revascularisation, 242 (39%) 
undergoing PCI and 78 (13%) undergoing CABG.
CAD-RADS 0 and CAD-RADS 1–2
Of the 1976 patients with normal coronary arteries (CAD- 
RADS 0), 39 (2%) underwent functional testing (func-
tional testing by CAD- RADS score is shown in figure 2) 
and 3 underwent ICA (ICA by CAD- RADS score is shown 
in figure 3) with no revascularisation.
Of the 1910 patients with atheroma probably not associ-
ated with ischaemia (CAD- RADS 1–2), functional imaging 
was used in 41 (2%) and ICA was used in 32 (2%). Two 
CAD- RADS 2 patients underwent PCI (figure 4).
In total, there were 3886 patients with normal coro-
nary arteries (CAD- RADS 0) or atheroma probably not 
associated with ischaemia (CAD- RADS 1–2). According 
to NICE CG95 (2016), this means that 77% of the diag-
nostic population and 73% of the total population would 
not need second- line investigation.
From both groups (CAD- RADS 0 and CAD- RADS 1–2), 
33 (94%) of 35 patients who underwent ICA did not 
undergo revascularisation (figure 5).
CAD-RADS 3–5
The diagnostic population with CAD- RADS 3, 4 or 5 
consisted of 1190 patients (23%). For these patients, 
functional testing for ischaemia (figure 2) was used in 
165 (30%) CAD- RADS 3 patients, 114 (21%) CAD- RADS 
4 patients and 8 (9%) CAD- RADS 5 patients. ICA was used 
in 125 (23%) CAD- RADS 3 patients, 345 (63%) CAD- 
RADS 4 patients and 62 (68%) CAD- RADS 5 patients 
(figure 3).
For the diagnostic population, revascularisation was 
performed in 33 (6%) CAD- RADS 3 patients, 221 (40%) 
CAD- RADS 4 patients and 46 (51%) CAD- RADS 5 patients 
(figure 4). Thus, 74% (92/125) of CAD- RADS 3 patients, 
36% (124/345) of CAD- RADS 4 patients, 26% (16/62) of 
CAD- RADS 5 patients underwent ICA but not revascular-
isation (figure 5). The majority of CAD- RADS 5 patients 
undergoing revascularisation were treated with PCI (59% 
(27/46)), and the rest underwent CABG.
Table 1 Patient numbers and characteristics by centre
Centre A B C D E F G H I Overall
Number of patients 1037 264 666 198 230 355 513 142 1888 5293
























































The overall data therefore refer to eight centres, 4627 patients.
*One centre did not submit data pertaining to age and BMI.
BMI, body mass index.
Figure 1 Coronary Artery Disease–Reporting and Data 
System (CR) distribution (%) for 5293 patients undergoing CT 
coronary angiography for chest pain assessment following 
National Institute for Health and Care Excellence–Clinical 
Guidance 95 (2016).
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When ICA was undertaken for CAD- RADS 3 or for a 
non- diagnostic CTCA, it was chosen in 88% (110/125) 
and 96% (49/51) of patients, respectively, as the second- 
line test.
Non-diagnostic CTCA
Of the 217 (4%) patients with a non- diagnostic CTCA, 
100 (46%) went on to have further investigation. Func-
tional testing for ischaemia and ICA were used equally 
as a second- line test (49 patients, 49% for both), and 
for two (2%) patients, ICA was used as a third- line test 
after functional testing for ischaemia. The non- diagnostic 
CTCA revascularisation rate (figure 4) was 8% (18/217) 
and 65% (33/51) of patients who underwent ICA but not 
revascularisation (figure 5).
DISCUSSION
This is the second BSCI/BSCCT national initiative aimed 
at improving CTCA service quality across the UK and 
follows on from the prospective national radiation dose 
survey of 2017.7 We have shown CTCA to be a robust diag-
nostic tool with 96% of scans being diagnostic, across a 
broad age range of patients, with a mean BMI of 29 kg/
m² and gender equality in application. Three- quarters 
of patients are ‘triaged’ by CTCA to not require further 
testing as there is a high probability that their chest pain 
symptoms are not due to ischaemia. Accordingly. the 
utilisation of downstream testing in patients from the 
CAD- RADS 0–2 group was very low, and only 2 of 3883 
patients underwent revascularisation with PCI. Neverthe-
less, a large subgroup of these patients (36% of the total 
population) have atheroma and have been identified as 
potential candidates for preventive therapies based on 
their CTCA result8; this group would not be identified 
with functional testing for ischaemia.
The total population ICA rate of 12% appears relatively 
modest. Furthermore, those patients selected for onward 
ICA with a CAD- RADS score of either 4 or 5 were likely 
to undergo revascularisation, at rates of 64% and 74%, 
respectively. Of the diagnostic population undergoing 
ICA, only 12% underwent CABG. Interestingly, even in 
the CAD- RADS 5 group, the mode of revascularisation 
was more commonly PCI (59% PCI vs 41% CABG). This 
later finding may be explained by the intrinsic challenges 
CTCA faces in differentiating between critical stenosis 
and a short, occluded segment.9 This is relevant to proce-
dural planning. Our data support the scheduling patients 
requiring ICA after CTCA for ICA±PCI rather than ICA 
as a second- line stand- alone diagnostic test.
Despite the clear recommendations in CG95 (2016) 
that ICA ought to be used as a third- line and not 
Table 2 Disease severity for 5076 patients with diagnostic CTCA at each of the nine sites and overall
Centre A B C D E F G H I Overall




























































CAD- RADS allows three distinct groups of patients to be defined: those with normal coronary arteries (CAD- RADS 0), those with atheroma 
probably not associated with ischaemia (CAD- RADS 1–2) and those with atheroma possibly or probably associated with ischaemia (CAD- 
RADS 3–5).
CAD- RADS, Coronary Artery Disease–Reporting and Data System; CTCA, CT coronary angiography.
Figure 2 Patients (%) undergoing functional testing* after 
all CT coronary angiography by Coronary Artery Disease–
Reporting and Data System (CR) score. *Includes patients 
undergoing functional testing as a third- line investigation 
after invasive coronary angiography had been used as a 
second- line investigation.
Figure 3 Invasive coronary angiography rates (%) after 
all CT coronary angiography by Coronary Artery Disease–
Reporting and Data System (CR) score
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second- line investigation when evidence of CAD of 
uncertain functional significance is found or if the CTCA 
is non- diagnostic, this advice is often not followed. ICA 
was frequently favoured as the second- line test, and this 
contributes to the high rate of ICA with no resulting 
revascularisation (48%). The conversely low ICA to PCI 
conversion rate of 39%, which is consistent with the rate 
described for the UK by Asher et al in 2019, remains disap-
pointingly low and could be improved.10 The ‘uncer-
tain functional significance’ of CAD- RADS 3 patients is 
worthy of further attention. Only 6% of the population 
with CAD- RADS 3 underwent revascularisation. This 
suggests that even the recommended ‘functional testing 
for ischaemia when diagnostic doubt remains’ (or indeed 
FFRCT) ought not to be used without serious consider-
ation. It would certainly seem that ‘blanket testing’ for 
all CTCA- detected coronary artery stenosis of uncertain 
functional significance is unnecessary. Indeed, less than 
10% (46/624) of patients who underwent either func-
tional testing for ischaemia or FFRCT also underwent 
revascularisation. Nevertheless, if second- line investi-
gation is indeed thought necessary in either clinical 
scenario, utilisation of functional testing for ischaemia, 
rather than ICA, would undoubtedly reduce the rate of 
duplicated coronary angiographic assessment with no 
resulting revascularisation.
The data presented in this report may help inform our 
discussions with patients. The likelihood of a variety of 
different outcomes is evident at different stages of the 
patient journey. For example, at the outset of stable 
recent- onset chest pain investigation, the likely need for 
follow- on testing after CTCA is low, and the chances of 
requiring CABG are very low (1%–2%). Patients may be 
listed for ICA because of ongoing clinical concerns and 
a moderate CTCA stenosis, but there is 74% chance it 
will not result in intervention. This report also allows 
follow- up consultation planning and economic model-
ling, with >70% of patients reasonably dischargeable back 
to their general practitioner after CTCA without further 
testing.
Therefore, in terms of service quality improvement, 
this may be achieved by taking the onward revasculari-
sation rate into account when considering the need for 
onward testing and then:
 ► Following NICE CG95 (2016) second- line investiga-
tion recommendations.
 ► Avoiding ‘stand- alone’ diagnostic ICA after CTCA 
wherever possible.
These measures may reduce the number of patients 
undergoing duplicated coronary angiographic assess-
ment with no resulting revascularisation. In turn, this 
may improve and facilitate the journey of patient with 
chest pain at less cost and risk.
Strengths and limitations
Our study provides extensive novel data regarding the 
contemporary investigation of patients with stable chest pain, 
although given the timing of data collection the findings may 
be considered as generally representative of the ‘pre- FFRCT 
era’. A major strength of this work is the prospective, multi-
centre design. The patient numbers are convincing, and the 
‘real- world’ nature of the data allows direct translation to 
clinical care. It is accepted that the reasons a cardiologist may 
undertake ICA after a CTCA are heterogeneous and unique 
to the individual patient. Unclear or suboptimal CTCA 
reporting may contribute to the decision- making process, 
and therefore ‘ICA with no resulting revascularisation’ or 
‘duplication of coronary angiographic assessment without 
revascularisation’ may be crude as a marker for ICA overuse 
in this context.
There are of course limitations to a service improvement 
initiative, which involves collection of data in an observa-
tional manner. There may be unadjusted confounding 
factors and referral bias. The report is intended to provide 
an overview of the national approach to downstream testing 
after a NICE CG95 (2016) CTCA, rather than an attempt to 
identify local geographical variation in patient populations 
or practice between centres. Every effort has been taken to 
ensure data collection was accurate and complete, including 
ensuring that data analysis was reassessed by each contrib-
uting centre to ensure accuracy. However, as with all anal-
yses involving healthcare records, these may be incomplete, 
inaccurate or unclear. One centre did not transfer data with 
clearly identified CAD- RADS scores and was excluded from 
Figure 4 Revascularisation rates after all CT coronary 
angiography by Coronary Artery Disease–Reporting and Data 
System (CR) score (%).
Figure 5 Proportion of patients undergoing invasive 
coronary angiography without revascularisation (%) after 
all CT coronary angiography by Coronary Artery Disease–
Reporting and Data System (CR) score.
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the analysis. Other centres successfully clarified any unclear 
or incomplete data entries.
CONCLUSIONS
CTCA for the NICE CG95 (2016) assessment and diagnosis 
of recent- onset chest pain has been considered as a robust 
and effective test. In all, 96% achieved a diagnostic scan, and 
of these, 73% of patients were CAD- RADS 0–2 and therefore 
should require no further onward investigation. However, 
12% underwent ICA and 48% of these had duplicated coro-
nary angiographic assessment with no resulting revasculari-
sation. In subgroups (CAD- RADS 3 and non- diagnostic scan 
patients), there is overuse of ICA as a second- line investiga-
tion, suggesting room for improvement in terms of compli-
ance with NICE CG95 (2016). Functional testing for cardiac 
ischaemia is recommended as second- line investigation for 
these subgroups although they have been shown to have low 
overall revascularisation rates (<10%), suggesting ‘blanket 
testing’ is unnecessary. For patients with severe disease (CAD- 
RADS 4 and 5), ICA generally leads to revascularisation (64% 
and 74%, respectively), commonly PCI, suggesting a default 
ICA±PCI approach is appropriate.
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